Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Duality BiotherapeuticsFRA:4ZB +6.49%19 Market Cap is €1,802.3 Mil as of Sep. 16, 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review. Among 1,419 Biotechnology companies, Duality Biotherapeutics ranks better than 88.23% on this metric.
Duality Biotherapeutics's quarterly market cap
increased
from Jun. 2025 (€2,260.4 Mil) to Dec. 2025 (€2,916.8 Mil) but then
declined
from Dec. 2025 (€2,916.8 Mil) to Jun. 2026 (€0.0 Mil).
Duality Biotherapeutics's annual market cap
stayed the same
from Dec. 2023 (€0.0 Mil) to Dec. 2024 (€0.0 Mil) but then
increased
from Dec. 2024 (€0.0 Mil) to Dec. 2025 (€2,916.8 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Duality Biotherapeutics's Enterprise Value for Today is €1,459.3 Mil.
Duality Biotherapeutics (FRA:4ZB) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Duality Biotherapeutics Market Cap Related Terms
Duality Biotherapeutics Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics Market Cap Chart
Duality Biotherapeutics Annual Data
Trend
Dec22
Dec23
Dec24
Dec25
Market Cap
0.00
0.00
0.00
2,916.83
Duality Biotherapeutics Semi-Annual Data
Jun25
Dec25
Jun26
Market Cap
2,260.45
2,916.83
0.00
FRA:4ZB vs VRTX, REGN, MRNA: Market Cap Comparison
For the Biotechnology subindustry, Duality Biotherapeutics's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Duality Biotherapeutics Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Market Cap distribution charts can be found below:
* The bar in red indicates where Duality Biotherapeutics's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Duality Biotherapeutics's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Duality Biotherapeutics (FRA:4ZB) has a Market Cap of €1,802.3 Mil as of Sep. 16, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Duality Biotherapeutics and its competitors. According to the industry distribution chart, Duality Biotherapeutics ranks #167 out of 1419 companies in the Biotechnology industry, placing it in the top 11.8%.
Is Duality Biotherapeutics' Market Cap too high?
Duality Biotherapeutics' current Market Cap is €1,802.3 Mil. Based on the distribution chart, Duality Biotherapeutics ranks #167 out of 1419 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Market Cap compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Duality Biotherapeutics ranks #167 out of 1419 companies for Market Cap. This places Duality Biotherapeutics in the top 12% of its industry — outperforming the majority of peers. The industry median Market Cap is 113.40. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 113.40, based on 1,419 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Duality Biotherapeutics and its competitors. For the Biotechnology industry, the median Market Cap is 113.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Duality Biotherapeutics's current Market Cap is €1,802.3 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Market Cap of €1,802.3 Mil. The current Market Cap is €1,802.3 Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Market Cap is €1,802.3 Mil as of Sep. 16, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score
Get the complete analysis for FRA:4ZB
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:4ZB has been successfully added to your 
